What does DAC stand for in CJC-1295?

DAC stands for Drug Affinity Complex. It's a chemical modification added to CJC-1295 that causes it to bind to albumin, a protein circulating in the bloodstream. That binding is what extends the compound's active half-life from minutes to several days, rather than a change to the core GHRH-analog sequence itself.

Is CJC-1295 with DAC or without DAC better?

Neither is straightforwardly "better," since no head-to-head controlled trial has compared the two forms directly. With DAC means fewer injections and a steadier baseline of activity, which some in the community see as an advantage, while others argue it doesn't replicate the body's natural pulsatile GH release as closely as the shorter-acting form. Without DAC allows dosing to be timed more precisely around natural GH pulse windows, like fasted mornings or before sleep, but requires more frequent injections. Both are genuinely discussed trade-offs, not a settled conclusion.

How often do you need to dose CJC-1295 without DAC compared to with DAC?

CJC-1295 without DAC (Mod GRF 1-29) has a short half-life similar to Sermorelin's, roughly 30 minutes, so it's generally discussed as a daily dosing pattern, often timed around fasted states and before bed. CJC-1295 with DAC has a half-life extending to several days because it binds albumin, so it's generally discussed as dosed once or twice a week.

Are CJC-1295 with DAC and without DAC the same compound?

They're the same underlying GHRH-analog core sequence, not two different compounds. CJC-1295 without DAC, also called Mod GRF 1-29, is essentially that core sequence on its own. CJC-1295 with DAC is that same sequence plus the Drug Affinity Complex modification that binds albumin and extends its half-life. The difference is the DAC modification itself, not a different active molecule.

Which form is used in the CJC-1295 and Ipamorelin stack?

Either form can be paired with Ipamorelin, and which one is in use changes how the whole stack is timed. The no-DAC form is dosed daily on a schedule similar to Ipamorelin's, while the DAC form is dosed only once or twice weekly alongside daily Ipamorelin. See the CJC-1295 and Ipamorelin stack guide for how that timing actually works in practice.

CJC-1295 With DAC vs Without DAC

Quick Comparison

Factor	With DAC	Without DAC
Half-life	Several days	Roughly 30 minutes, similar to Sermorelin
Typical dosing frequency (community-discussed)	Once or twice weekly	Daily, often fasted and/or before bed
Binding mechanism	Binds serum albumin via the DAC modification	No albumin binding; clears like the unmodified GHRH fragment
Discussed trade-off	Fewer injections, steadier baseline activity; some argue it's less pulsatile	Can be timed closer to natural GH pulses; requires more frequent injections
Evidence base	No dedicated large-scale human trials; general GHRH-pathway science	No dedicated large-scale human trials; general GHRH-pathway science

One Compound, Two Forms

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Both versions discussed here share the same GRF(1-29)-based core sequence, the part of the molecule that actually binds and activates the GHRH receptor. This is worth stating plainly because the naming convention makes it easy to read "with DAC" and "without DAC" as two different compounds being compared, the way BPC-157 and TB-500 might be. They aren't. The difference between the two forms covered on this page is a single added modification, not a different active molecule.

What DAC Actually Does

DAC stands for Drug Affinity Complex. It's a chemical tag added to the CJC-1295 sequence that causes the molecule to bind reversibly to albumin, a protein that circulates abundantly in the bloodstream. That albumin binding is what dramatically extends the compound's active half-life, from minutes to several days, because the bound complex is cleared far more slowly than the free peptide would be. The practical result is that far less frequent dosing is needed to maintain elevated activity. The community generally discusses this as once or twice weekly, in contrast to a daily schedule for the unmodified form.

CJC-1295 Without DAC (Mod GRF 1-29)

CJC-1295 without DAC is commonly called Mod GRF 1-29. It's essentially the same GHRH-analog core sequence without the albumin-binding addition. Left unmodified, it behaves like a short-acting GHRH fragment, with a half-life discussed as similar to Sermorelin's, roughly 30 minutes. Because it clears the bloodstream quickly, it requires more frequent dosing to produce a comparable cumulative effect, generally discussed as a daily schedule rather than weekly. Timing is usually framed around fasted states and before bed, aligning injections with the body's natural, pulsatile pattern of growth hormone release rather than trying to hold a constant elevated level.

The Trade-Off the Community Actually Debates

Neither form is presented here as objectively superior, because no head-to-head controlled trial comparing the two exists. What exists instead is a genuinely discussed trade-off within the research community, and it's worth laying out both sides plainly rather than picking a winner.

The case for DAC centers on convenience and a steadier baseline: fewer injections per week, and sustained receptor stimulation rather than a single brief spike. The case against it, as some in the community argue, is that a constant elevated signal doesn't replicate the body's natural pulsatile GH release pattern as closely as a short-acting form timed around specific windows does. The case for no-DAC is the inverse: dosing can be timed more precisely around fasted mornings or pre-sleep, working with the body's natural pulse pattern rather than overriding it, but at the cost of needing an injection every day instead of once or twice a week.

Why this framing matters: this is a discussed trade-off, not a settled clinical conclusion. Anyone claiming one form is definitively "better" for outcomes is going beyond what a head-to-head trial has actually established, because that trial doesn't exist yet.

Evidence Base

Neither form has dedicated large-scale human trials of its own. What evidence exists rests mainly on the broader GHRH-receptor mechanism, much of it understood through research on related compounds like Sermorelin, rather than on trials specific to either the DAC-extended or unmodified version of CJC-1295. See CJC-1295 Human Studies for the fuller picture of what is and isn't established, including the one dedicated pharmacokinetic study of the DAC form's half-life.

Why This Matters for Stacking

This distinction isn't academic if you're actually planning a protocol. It matters directly for anyone looking at the CJC-1295 and Ipamorelin stack, since that stack's entire dosing pattern, daily versus once or twice weekly for the CJC-1295 side, depends on which form of CJC-1295 is actually in the product being used. Confirming which form a product contains before planning a schedule is a practical first step, not an afterthought. See that guide for where the practical timing and stacking implications are worked out in full.

Bloodwork to Track

IGF-1 is the standard marker for tracking growth-hormone-axis activity for either form, since growth hormone itself is released in short pulses that are difficult to catch on a single blood draw. See the peptide bloodwork guide for what a baseline panel typically includes.

For the full compound reference, see CJC-1295. For the honest evidence picture on both forms, see CJC-1295 Human Studies. For the practical stacking implications of this DAC distinction, see the CJC-1295 and Ipamorelin stack guide. For how CJC-1295 compares against a different GHRH-pathway compound entirely, see CJC-1295 vs Sermorelin and CJC-1295 vs Ipamorelin. BioStackIQ's Rate My Stack and Build Protocol can help you think through which form fits a given schedule.

Frequently Asked Questions

Disclaimer: This content is for informational purposes only and does not constitute medical advice. CJC-1295, with or without DAC, is not currently sold as an FDA-approved prescription product. Always consult a qualified healthcare provider before starting any peptide protocol.